Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Return on Assets for 10 consecutive years, with 0.09% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets rose 195.0% to 0.09% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.09%, a 195.0% increase, with the full-year FY2023 number at 0.76%, down 12.0% from a year prior.
  • Return on Assets was 0.09% for Q3 2025 at Crescent Biopharma, up from 0.29% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.09% in Q3 2025 to a low of 3.16% in Q1 2025.
  • A 5-year average of 0.88% and a median of 0.71% in 2023 define the central range for Return on Assets.
  • Biggest YoY gain for Return on Assets was 195bps in 2025; the steepest drop was -222bps in 2025.
  • Crescent Biopharma's Return on Assets stood at 0.63% in 2021, then tumbled by -38bps to 0.87% in 2022, then grew by 14bps to 0.75% in 2023, then plummeted by -173bps to 2.04% in 2024, then skyrocketed by 96bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Return on Assets are 0.09% (Q3 2025), 0.29% (Q2 2025), and 3.16% (Q1 2025).